Universal Cells News Today

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) and NanoString Technologies (NASDAQ:NSTG – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk. Valuation and Earnings This table compares Adaptimmune […]

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) and Revolution Medicines (NASDAQ:RVMD – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership. Insider and Institutional Ownership 14.6% of Adaptimmune Therapeutics […]

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) and Vaxcyte (NASDAQ:PCVX – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership. Volatility & Risk Adaptimmune Therapeutics has a beta of […]

Vaxcyte (NASDAQ:PCVX – Get Free Report) and Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations. Analyst Recommendations This is a breakdown of current ratings […]

Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) and Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership. Analyst Ratings This is a summary of […]

Engraftment of Vertex Pharmaceuticals VX-880 stem cell–derived islets has now been achieved in six patients, two of whom are insulin-independent at 1 year.

Astellas Pharma agreed to acquire Iveric Bio for approximately $5.9 billion, in a deal designed to expand the buyer’s eye treatment pipeline.

Adaptimmune and TCR2 Therapeutics have complementary technologies and an aligned strategy of developing cell therapies for solid tumors, but this marriage is preceded by divorce. Before consummating the TCR2 deal, Adaptimmune ended an alliance with a larger pharmaceutical company.

BLA submission initiated for afami-cel, with aim to complete in mid-2023; afami-cel has the potential to be the first marketed engineered TCR T-cell therapy for a solid tumor52% (13/25) response rate

To advance the field of immuno-oncology, we must shift our mindsets and ways of working to embrace agile practices and new levels of knowledge...